Ghent (Belgium), 22 December 2023, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, had asked for its shares to be suspended from trading following interest from a strategic investor in acquiring a 30% stake.
Author: bonyf
Post
bonyf’s 2022 financial statements made available
Ghent (Belgium), 20 July 2023, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, presents its 2022 consolidated financial statements, approved by its Board of Directors and audited by its Statutory Auditors
Post
Delay in release of financial statements 2022
Ghent (Belgium), 30 June 2023; bonyf NV (Mnemonic: MLBON), a leading manufacturer of oral and denture care products announces its delay in the preparation and audit of the financial statements for the 2022 financial year.
Post
bonyf exhibits at the largest private label trade show
VADUZ, Liechtenstein, 12 May 2023 – bonyf, a leading manufacturer of oral and denture care products is excited to announce its participation in the Private Label Manufacturers Association's (PLMA) annual trade show in Amsterdam.
Post
Trading Suspension
Ghent (Belgium), 24 February 2023, 6:00 p.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, announces the suspension of the listing of its shares at the request of the company.
Post
bonyf is granted TFDA approval in Taiwan
VADUZ, Liechtenstein, 13 February 2023 – To comply with new stringent regulations enforced in Taiwan for the sale of medical device products, bonyf has received the TFDA (Taiwan Food and Drug Administration) approval for 2 core products.
Post
Inaugural shareholder newsletter released
GHENT, Belgium, 21 December 2022 – bonyf NV releases to its new shareholders the inaugural shareholder newsletter. The shareholder newsletter has been released by bonyf’s CEO and Founder, Mr Jean-Pierre Bogaert.
Post
25% increase in turnover in H1 2022
Ghent (Belgium), 14 September, 2022, 6 p.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, announces a strong growth in turnover for the first half of 2022 ...
Post
bonyf initiates a second clinical study to document the safety and efficacy of AphtoFix®, the company’s patented and unique muco-adhesive cream that treats mouth ulcers
VADUZ, Liechtenstein, 19 July 2022 – To comply with the new European Medical Device Regulation, bonyf has officially initiated a second clinical safety and efficacy evaluation study of its mouth ulcer cream ...
Post
Annual results 2021
Ghent (Belgium), 30 June, 2022, 7 p.m.; bonyf NV (ticker symbol: MLBON), the next-generation oral comfort expert, presents its 2021 financial statements, approved by ...